Danaher Corporation agreed to acquire Masimo for $9.9 billion in cash, offering $180 per share and a roughly 38% premium to Masimo’s last close, the companies disclosed. The transaction will fold Masimo’s patient‑monitoring and noninvasive diagnostics portfolio into Danaher’s diagnostics and life‑science businesses and is positioned as a strategic move to expand Danaher’s clinical monitoring capabilities. Company statements and the deal filing emphasize synergies in diagnostics, stronger distribution channels, and investment to scale Masimo’s product lines. The acquisition is a classic strategic consolidation in med‑tech: buyers cited the asset fit and revenue‑mix improvements while Masimo shareholders will assess the premium versus long‑term standalone upside. Regulators and integration timelines remain the next checkpoints; Danaher and Masimo said they expect the deal to close after customary approvals and shareholder consent.